Sign in
Taking people in United StatesPhase 3

Sacubitril-valsartan for heart shape and pumping in congenital heart disease

Tests sacubitril-valsartan against placebo in adults with congenital heart disease.

Key facts

Who runs it
Mayo Clinic
Where
Rochester, United StatesSee the site
Trial code
Registry title
Effect of Sacubitril-Valsartan on Cardiac Structure and Function
Status
Recruiting
Phase
Phase 3
People taking part
45 people, planned
Started
3 Feb 2025
Expected to end
Aug 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Entresto Pill
  • Placebo
Record updated
9 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with congenital heart disease, meaning a heart problem present from birth. Participants get Entresto (sacubitril-valsartan) or a placebo (dummy pill).

Age
18 years or older
Sex
All sexes
Disease stage
A diagnosis of congenital heart disease
Earlier treatment
People cannot join if they currently take an ACE inhibitor, ARB or ARNI. Other listed drugs also rule people out: Amifostine, Droperidol, Dantrolene, CYP3A4 Inhibitors, Obinutuzumab, Aliskiren, Lithium, Sparsentan.

Main reasons for not taking part

  • Stage IV chronic kidney disease (creatinine clearance <30 ml/min)
  • High blood potassium (serum potassium >5.2 mmol/l)
  • Low blood pressure (systolic blood pressure <100 mmHg)
  • Past swelling (angioedema) from ACE or ARB drugs
  • Pregnancy, or diabetes treated with Aliskiren

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Congenital Heart Disease Diagnosis
  • Age 18 or Older

Who cannot take part

  • History of angioedema related to previous ACE or ARB therapy
  • Drug Therapies; Amifostine; Droperidol; Dantrolene; CYP3A4 Inhibitors; Obinutuzumab; Aliskiren; Lithium; Sparsentan; ACE inhibitor; ARB; ARNI
  • Patients diagnosed with diabetes using Aliskiren,
  • Stage IV chronic kidney disease defined as creatinine clearance <30 ml/min
  • Hyperkalemia defined as serum potassium >5.2 mmol/l,
  • Hypotension defined as systolic blood pressure <100 mmHg,
  • Pregnancy

Where in United States

  • Mayo Clinic in RochesterRochester, United StatesContact: Amanda WozniakTaking people

About the trial

What the trial wants to find out

The purpose of this study is to compare changes in cardiac structure and function, biomarkers, and patient reported outcomes between adults with congenital heart disease (ACHD) randomized to angiotensin receptor-neprilysin inhibitor (ARNI) therapy vs placebo.

The 2 groups in the trial

  • EntrestoTreatment being tested

    Treatment: Entresto Pill

  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Effect of Sacubitril-Valsartan on Cardiac Structure and Function in Adults With Congenital Heart Disease
Plain-language title
Sacubitril-valsartan for heart shape and pumping in congenital heart diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
9 October 2026